Johnson & Johnson (JNJ)vsKiniksa Pharmaceuticals Ltd (KNSA)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
KNSA
Kiniksa Pharmaceuticals Ltd
$95.18
+6.70%
HEALTHCARE · Cap: $6.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 11714% more annual revenue ($99.33B vs $840.85M). JNJ leads profitability with a 16.2% profit margin vs 9.6%. JNJ trades at a lower P/E of 38.8x. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
KNSA
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Margin of Safety
+77.3%
Fair Value
$198.47
Current Price
$95.18
$103.29 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Revenue surging 55.4% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 30.4% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Trading at 11.3x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity, EPS Growth. Revenue growth of 55.4% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : KNSA
The primary concerns for KNSA are Price/Book, P/E Ratio. A P/E of 79.4x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while KNSA is a hypergrowth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
KNSA is growing revenue faster at 55.4% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 53/100), backed by strong 16.2% margins. KNSA offers better value entry with a 77.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?